<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01872598</url>
  </required_header>
  <id_info>
    <org_study_id>AB09004</org_study_id>
    <nct_id>NCT01872598</nct_id>
  </id_info>
  <brief_title>Masitinib in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of masitinib for the treatment
      of mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in
      patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase
      inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Actual standard treatment for mild to moderately severe Alzheimer's dementia includes
      acetylcholinesterase inhibitors (donepezil, rivastigmine and galantamine) and a NMDA receptor
      antagonist (memantine for moderate to severe Alzheimer's disease). These medications have
      shown to have an effect on some cognitive and non cognitive symptoms of the pathology.
      However, their efficacy remains limited and may decrease with time. There is an unmet medical
      need in this pathology. Masitinib is a selective tyrosine kinase inhibitor that is thought to
      exert a neuroprotective effect through its activity on mast cells and other non-neuronal
      cells of the central nervous system, with subsequent modulation of inflammatory and
      neurodegenerative processes, as well as possibly disruption of the Aβ signaling cascade via
      inhibition of the Fyn signaling pathway. This is a multicenter, double-blind, randomized,
      placebo-controlled, parallel-group study of oral masitinib. The objective of this study is to
      compare the efficacy and safety of masitinib at various doses versus matched placebo in the
      treatment of patients with mild to moderate Alzheimer's Disease. Masitinib will be
      administered as add-on therapy in patients who have been treated for a minimum of 6 months
      with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine)
      and/or memantine. Approximately 675 patients will be randomized into 5 treatment groups. The
      co-primary outcome measures are the Alzheimer's Disease Cooperative Study Activities of Daily
      Living score (ADCS-ADL), and Alzheimer's Disease Assessment Scale-Cognitive Subscale score
      (ADAS-Cog) after 24 weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADCS-ADL</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in the Alzheimer's Disease Cooperative Study Activities of Daily Living score (ADCS-ADL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADAS-Cog</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale score (ADAS-Cog).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMSE</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in Mini Mental State Examination (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIBIC-plus</measure>
    <time_frame>24 weeks</time_frame>
    <description>Clinician's Interview Based Impression of Change-plus (CIBIC-plus)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">721</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Masitinib escalating dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Masitinib fixed dose (4.5 mg/kg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Masitinib fixed dose (3.0 mg/kg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (escalating dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (fixed dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive fixed dose placebo, given orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib</intervention_name>
    <arm_group_label>Masitinib escalating dose</arm_group_label>
    <arm_group_label>Masitinib fixed dose (3.0 mg/kg/day)</arm_group_label>
    <arm_group_label>Masitinib fixed dose (4.5 mg/kg/day)</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (escalating dose)</arm_group_label>
    <arm_group_label>Placebo (fixed dose)</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria include:

          1. Patient with dementia of Alzheimer's type, according to the Diagnostic and Statistical
             Manual of Mental Disorders criteria (DSM-IV)

          2. Patient with probable Alzheimer' disease according to the National Institute of
             Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and
             Related Disorders Association criteria (NINCDS-ADRDA)

          3. Patient with MMSE ≥ 12 and ≤ 25 at baseline

          4. Patient treated for a minimum of 6 months with a stable dose of cholinesterase
             inhibitors (donepezil, rivastigmine or galantamine) at baseline, and/or a stable dose
             of memantine for a minimum of 6 months at baseline, with no changes foreseen in
             therapy throughout the study.

        Exclusion criteria include:

          1. Patient with any other cause of dementia not due to Alzheimer's disease.

          2. Patient with Alzheimer disease with severe forms of delusions or delirium (patients
             with light and mild forms of delusions and delirium will be allowed in the study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno DUBOIS, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié-Salpétrière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT Sveta Marina</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia Stołeczna 7</name>
      <address>
        <city>Białystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Elias</name>
      <address>
        <city>Bucuresti</city>
        <zip>013686</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Dnipropetrovsk Regional Clinical Hospital named after I.I. Mechnikov</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Greece</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>dementia</keyword>
  <keyword>cognitive disease</keyword>
  <keyword>memory loss</keyword>
  <keyword>cerebrovascular disease</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

